213 related articles for article (PubMed ID: 35699088)
1. Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.
Shiono A; Imai H; Wasamoto S; Tsuda T; Nagai Y; Minemura H; Yamada Y; Kishikawa T; Umeda Y; Takechi H; Yamaguchi O; Mouri A; Kaira K; Taniguchi H; Minato K; Kagamu H
Cancer Med; 2023 Jan; 12(1):73-83. PubMed ID: 35699088
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Imai H; Nagai Y; Minemura H; Tsuda T; Yamada Y; Wasamoto S; Kishikawa T; Shiono A; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Kanazawa K; Taniguchi H; Minato K; Kagamu H
Invest New Drugs; 2022 Oct; 40(5):1066-1079. PubMed ID: 35749041
[TBL] [Abstract][Full Text] [Related]
3. Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer.
Tsuda T; Imai H; Nagai Y; Umeda Y; Shiono A; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Ishizuka T; Taniguchi H; Kagamu H
Oncol Lett; 2023 Mar; 25(3):111. PubMed ID: 36817046
[TBL] [Abstract][Full Text] [Related]
4. Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Kim SH; Jo EJ; Mok J; Lee K; Kim KU; Park HK; Lee MK; Eom JS; Kim MH
Korean J Intern Med; 2023 Mar; 38(2):218-225. PubMed ID: 36800677
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
Liu SV; Mok TSK; Nabet BY; Mansfield AS; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair MJ; Garassino MC; Gay CM; Heymach JV; Byers LA; Lam S; Cardona A; Morris S; Adler L; Shames DS; Reck M
Lung Cancer; 2023 Dec; 186():107418. PubMed ID: 37931445
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of chemotherapy, especially combined therapy with Carboplatin Plus Etoposide(CE), in patients aged > or =80 years old with extensive-disease small-cell lung cancer].
Tamiya A; Tsuya A; Nakamura Y; Kaira K; Naitou T; Murakami H; Takahashi T; Endo M; Yamamoto N
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1041-4. PubMed ID: 20567104
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
Shimokawa T; Okamoto H; Machida R; Misumi Y; Hosomi Y; Yoneshima Y; Tanaka H; Okishio K; Simizu J; Goto K; Akamatsu H; Kubota K; Nakagawa K; Horinouchi H; Ando M; Kataoka T; Ohe Y
Lung Cancer; 2023 Jul; 181():107195. PubMed ID: 37156212
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab: A Review in Extensive-Stage SCLC.
Frampton JE
Drugs; 2020 Oct; 80(15):1587-1594. PubMed ID: 32990939
[TBL] [Abstract][Full Text] [Related]
10. Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.
Kim H; Choi E; Heo MH; Kim JY; Park KU
Oncology; 2022; 100(6):313-319. PubMed ID: 35390786
[TBL] [Abstract][Full Text] [Related]
11. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Ishii H; Azuma K; Shimose T; Yoshioka H; Kurata T; Shingu N; Okamoto M; Kawashima Y; Okamoto I
Thorac Cancer; 2023 Jan; 14(1):105-107. PubMed ID: 36380738
[TBL] [Abstract][Full Text] [Related]
14. Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
Igawa S; Shirasawa M; Ozawa T; Nishinarita N; Okuma Y; Ono T; Sugimoto A; Kurahayashi S; Sugita K; Sone H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Thorac Cancer; 2018 Aug; 9(8):967-973. PubMed ID: 29870153
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.
Lee S; Shim HS; Ahn BC; Lim SM; Kim HR; Cho BC; Hong MH
Cancer Immunol Immunother; 2022 May; 71(5):1093-1101. PubMed ID: 34568975
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
Kubo S; Kobayashi N; Matsumoto H; Somekawa K; Kaneko A; Hashimoto H; Teranishi S; Watanabe K; Horita N; Hara Y; Kudo M; Kaneko T
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17419-17426. PubMed ID: 37878090
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
Bria E; Morgillo F; Garassino MC; Ciardiello F; Ardizzoni A; Stefani A; Verderame F; Morabito A; Chella A; Tonini G; Gilli M; Del Signore E; Berardi R; Mencoboni M; Bearz A; Delmonte A; Migliorino MR; Gridelli C; Pazzola A; Iero M; De Marinis F
Oncologist; 2024 May; 29(5):e690-e698. PubMed ID: 38377176
[TBL] [Abstract][Full Text] [Related]
18. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L; Mansfield AS; Szczęsna A; Havel L; Krzakowski M; Hochmair MJ; Huemer F; Losonczy G; Johnson ML; Nishio M; Reck M; Mok T; Lam S; Shames DS; Liu J; Ding B; Lopez-Chavez A; Kabbinavar F; Lin W; Sandler A; Liu SV;
N Engl J Med; 2018 Dec; 379(23):2220-2229. PubMed ID: 30280641
[TBL] [Abstract][Full Text] [Related]
19. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Wasamoto S; Imai H; Tsuda T; Nagai Y; Minemura H; Yamada Y; Umeda Y; Kishikawa T; Shiono A; Kozu Y; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Kanazawa K; Taniguchi H; Kaburagi T; Minato K; Kagamu H
Front Oncol; 2022; 12():1080729. PubMed ID: 36741711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
